Subtractive proteomic analysis of antigenic extracellular proteins and design a multi-epitope vaccine against Staphylococcus aureus.
ESKAPE pathogen
Staphylococcus aureus
immunoinformatics
multi-epitopes vaccine
subtractive proteomic analysis
Journal
Microbiology and immunology
ISSN: 1348-0421
Titre abrégé: Microbiol Immunol
Pays: Australia
ID NLM: 7703966
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
08
12
2020
received:
27
10
2020
accepted:
21
12
2020
pubmed:
29
12
2020
medline:
1
10
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Staphylococcus aureus is a versatile Gram's positive bacterium that can reside as an asymptomatic colonizer, which can cause a wide range of skin, soft-tissue, and nosocomial infections. A vaccine against multi-drug resistant S. aureus, therefore, is urgently needed. Subtractive proteomics and reverse vaccinology are newly emerging techniques to design multiepitope-based vaccines. The analysis of 7290 proteomes (sensitive and resistant strains), five potent nonhuman homologous vaccine targets [(UNIPORT ID Q2FZL3 (Staphopain B), Q2G2R8 (Staphopain A), Q2FWP0 (uncharacterized leukocidin-like protein 1), Q2G1S6 (uncharacterized protein), and Q2FWV3 (Staphylokinase, putative)] were selected. These proteins were absent in the gut microbiome, which further enhances the significance of these proteins in vaccine design. These five virulence-associated proteins mainly have a role in the invasion mechanism in the host phagocyte cells. MHC I, MHC II, and B cell epitopes were identified in these five proteins. Finalized epitopes were examined by different online servers to screen suitable epitopes for multi-epitope based vaccine design. Shortlisted antigenic and nonallergenic associated epitopes were joined with linkers to design 30 variants (VSA1-VSA30) of multi-epitope vaccine conjugates. The antigenicity and allergenicity of all the 30 vaccine constructs were identified, and VSA30 was found to have the highest antigenicity and lowest allergenicity, and hence was selected for further study. Accordingly, VSA30 was docked with different HLA allelic variants, and the best-docked complex (VSA30-1SYS) was further analyzed by molecular dynamics simulation (MDS). The MDS result confirms the interaction of VSA30 with MHC (HLA-allelic variant). Thus, the final vaccine construct was in silico cloned in the pET28a vector for suitable expression in a heterologous system. Therefore, the designed vaccine construct VSA-30 can be developed as an appropriate vaccine to target S. aureus infection. VSA-30 still needs experimental validation to assure the antigenic and immunogenic properties.
Identifiants
pubmed: 33368661
doi: 10.1111/1348-0421.12870
doi:
Substances chimiques
Epitopes, B-Lymphocyte
0
Epitopes, T-Lymphocyte
0
Vaccines, Subunit
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
302-316Informations de copyright
© 2020 The Societies and John Wiley & Sons Australia, Ltd.
Références
Fowler VG, Jr, Proctor RA. Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect. 2014;20:66-75.
Khamash DF, Voskertchian A, Tamma PD, Akinboyo IC, Carroll KC, Milstone AM. Increasing clindamycin and trimethoprim-sulfamethoxazole resistance in pediatric Staphylococcus aureus Infections. J Pediatric Infect Dis Soc. 2018;8:351-3.
Otto M. Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin Biol Ther. 2010;10:1049-59.
Parker D. A live vaccine to Staphylococcus aureus infection. Virulence. 2018;9:700-2.
Nanra JS, Buitrago SM, Crawford S, et al. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother. 2013;9:480-7.
Adhikari RP, Thompson CD, Aman MJ, Lee JC. Protective efficacy of a novel alpha hemolysin subunit vaccine (AT62) against Staphylococcus aureus skin and soft tissue infections. Vaccine. 2016;34:6402-7.
Giersing BK, Dastgheyb SS, Modjarrad K, Moorthy V. Status of vaccine research and development of vaccines for Staphylococcus aureus. Vaccine. 2016;34:2962-6.
Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine. 2004;22:880-7.
Fattom A, Matalon A, Buerkert J, Taylor K, Damaso S, Boutriau D. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. Hum Vaccin Immunother. 2015;11:632-41.
Paling FP, Olsen K, Ohneberg K, et al. Risk prediction for Staphylococcus aureus surgical site infection following cardiothoracic surgery; a secondary analysis of the V710-P003 trial. PLoS One. 2018;13:e0193445.
Frenck RW, Creech CB, Sheldon EA, et al. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): results from a first-in-human randomised, placebo-controlled phase 1/2 study. Vaccine. 2017;35:375-84.
Begier E, Seiden DJ, Patton M, et al. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Vaccine. 2017;35:1132-9.
Landrum ML, Lalani T, Niknian M, et al. Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults. Hum Vaccin Immunother. 2017;13:791-801.
Lacey KA, Leech JM, Lalor SJ, McCormack N, Geoghegan JA, McLoughlin RM. The Staphylococcus aureus cell wall-anchored protein clumping factor A is an important T cell antigen. Infect Immun. 2017;85:e00549-17.
Zhang F, Jun M, Ledue O, Herd M, Malley R, Lu YJ. Antibody-mediated protection against Staphylococcus aureus dermonecrosis and sepsis by a whole cell vaccine. Vaccine. 2017;35:3834-43.
Aqib AI, Anjum AA, Ijaz M, et al. Development and evaluation of vaccine against Staphylococcus aureus recovered from naturally occurring mastitis in she-camels. Microb Pathog. 2018;117:341-7.
Wang X, Thompson CD, Weidenmaier C, Lee JC. Release of Staphylococcus aureus extracellular vesicles and their application as a vaccine platform. Nat Commun. 2018;9:1379.
Yu W, Yao D, Yu S, et al. Protective humoral and CD4+ T cellular immune responses of Staphylococcus aureus vaccine MntC in a murine peritonitis model. Sci Rep. 2018;8:3580.
Moscoso M, García P, Cabral MP, Rumbo C, Bou G. A D-alanine auxotrophic live vaccine is effective against lethal infection caused by Staphylococcus aureus. Virulence. 2018;9:604-20.
Yang L, Zhou H, Cheng P, et al. A novel bivalent fusion vaccine induces broad immunoprotection against Staphylococcus aureus infection in different murine models. Clin Immunol. 2018;188:85-93.
Reddy PN, Srirama K, Dirisala VR. An update on clinical burden, diagnostic tools, and therapeutic options of Staphylococcus aureus. Infect Dis. 2017;10:1179916117703999.
Bendtsen J, Nielsen H, Widdick D, Palmer T, Brunak S. Prediction of twin-arginine signal peptides. BMC Bioinformatics. 2005;6:167.
Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods. 2011;8:785-6.
Bagos PG, Tsirigos KD, Liakopoulos TD, Hamodrakas SJ. Prediction of lipoprotein signal peptides in gram-positive bacteria with a Hidden Markov Model. J Proteome Res. 2008;7:5082-93.
Krogh A, Larsson B, von Heijne G, Sonnhammer ELL. Predicting transmembrane protein topology with a Hidden Markov Model: application to complete genomes. J Mol Biol. 2001;305:567-80.
Yu NY, Wagner JR, Laird MR, et al. PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics. 2010;26:1608-15.
Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007;8:4.
Gao F, Luo H, Zhang CT, Zhang R. Gene essentiality analysis based on DEG 10, an updated database of essential genes. Methods Mol Biol. 2015;1279:219-33.
Chen L. VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res. 2005;33:D325-8.
Ramos PIP, Fernández Do Porto D, Lanzarotti E, et al. An integrative, multi-omics approach towards the prioritization of Klebsiella pneumoniae drug targets. Sci Rep. 2018;8:10755.
Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44:D457-62.
Szklarczyk DA, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447-52.
Kim Y, Ponomarenko J, Zhu Z, et al. Immune epitope database analysis resource. Nucleic Acids Res. 2012;40:W525-30.
Stranzl T, Larsen MV, Lundegaard C, Nielsen M. NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics. 2010;62:357-68.
Giguère S, Drouin A, Lacoste A, Marchand M, Corbeil J, Laviolette F. MHC-NP: predicting peptides naturally processed by the MHC. J Immunol Methods. 2013;400-401:30-6.
Nielsen M, Andreatta M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 2016;8:33.
Calis JJA, Maybeno M, Greenbaum JA, et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol. 2013;9:e1003266.
Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 2008;4:e1000048.
Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Raghava GPS. In silico approach for predicting toxicity of peptides and proteins. PLoS One. 2013;8:e73957.
El-Manzalawy Y, Dobbs D, Honavar V. Predicting linear B-cell epitopes using string kernels. J Mol Recognit. 2008;21:243-55.
El-Manzalawy Y, Dobbs D, Honavar V. Predicting flexible length linear B-cell epitopes. Comput Syst Bioinformatics Conf. 2008;7:121-32.
Larsen JE, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006;2:2.
Thomsen M, Lundegaard C, Buus S, Lund O, Nielsen M. MHCcluster, a method for functional clustering of MHC molecules. Immunogenetics. 2013;65:655-65.
Cheng J, Randall AZ, Sweredoski MJ, Baldi P. Scratch: a protein structure and structural feature prediction server. Nucleic Acids Res. 2005;33:W72-6.
Magnan CN, Randall A, Baldi P. SOLpro: accurate sequence-based prediction of protein solubility. Bioinformatics. 2009;25:2200-7.
Mashiach E, Schneidman-Duhovny D, Peri A, Shavit Y, Nussinov R, Wolfson HJ. An integrated suite of fast docking algorithms. Proteins. 2010;78:3197-204.
Verma P, Tiwari M, Tiwari V. In silico high-throughput virtual screening and molecular dynamics simulation study to identify inhibitor for AdeABC efflux pump of Acinetobacter baumannii. J Biomol Struct Dyn. 2018;36:1182-94.
Tiwari V, Patel V, Tiwari M. In-silico screening and experimental validation reveal L-adrenaline as anti-biofilm molecule against biofilm-associated protein (Bap) producing Acinetobacter baumannii. Int J Biol Macromol. 2018;107:1242-52.
Dhasmana D, Singh A, Shukla R, Tripathi T, Garg N. Targeting nucleotide binding domain of multidrug resistance-associated protein-1 (MRP1) for the reversal of multi drug resistance in cancer. Sci Rep. 2018;8:11973.
Grote A, Hiller K, Scheer M, et al. JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 2005;33:W526-31.
Carbone A, Zinovyev A, Kepes F. Codon adaptation index as a measure of dominating codon bias. Bioinformatics. 2003;19:2005-15.
Shaw L, Golonka E, Potempa J, Foster SJ. The role and regulation of the extracellular proteases of Staphylococcus aureus. Microbiology. 2004;150:217-28.
Bokarewa MI, Jin T, Tarkowski A. Staphylococcus aureus: staphylokinase. Int J Biochem Cell Biol. 2006;38:504-9.
Mancini F, Monaci E, Lofano G, et al. One dose of Staphylococcus aureus 4C-Staph vaccine formulated with a novel TLR7-dependent adjuvant rapidly protects mice through antibodies, effector CD4+ T cells, and IL-17A. PLoS One. 2016;11:e0147767.
Lacey KA, Geoghegan JA, McLoughlin RM. The role of Staphylococcus aureus virulence factors in skin infection and their potential as vaccine antigens. Pathogens. 2016;5:22.
Bazhan SI, Antonets DV, Karpenko LI, et al. In silico designed Ebola virus T-cell multi-epitope DNA vaccine constructions are immunogenic in mice. Vaccines. 2019;7:34.
Mustafa AS. In silico analysis and experimental validation of Mycobacterium tuberculosis-specific proteins and peptides of Mycobacterium tuberculosis for immunological diagnosis and vaccine development. Med Princ Pract. 2013;22:43-51.